What is the safety prospect of Roxogesic?
- Comparing to other NSAIDs, one of Loxoprofen advantages (Pro-drugs) as it is widely used for clinical purposes because they are not so harmful to the gastrointestinal mucosa
- On other hand, NSAIDs e.g. Indomethacin & Celecoxib have direct cytotoxicity “ability to induce necrosis and apoptosis in gastric mucosal cells” due to their membrane permeabilizing activities, which is involved in NSAID-induced gastric lesions, Indomethacin and Celecoxib clearly induce necrosis and apoptosis
- Loxoprofen and its active metabolite Loxoprofen-OH, do not have such effects in primary culture of guinea pig gastric mucosal cells
- Loxoprofen one of the most suitable NSAID for Elderly due to its high tolerability and comparable safety due its characteristic feature as Prodrug
- In Japan, Loxoprofen is considered as an effective treatment for elderly’ patients with refractory Nocturia Secondary to BPH “Benign Prostatic Hyperplasia” in the short-term approach
- Loxoprofen, in comparison to other NSAIDs, seems to be devoid of detrimental effects on renal function
What about its interaction with other medical products?
Roxogesic should be administered with care when co-administered with the following drugs Coumarine-type anticoagulants as warfarin, Sulphonyl urea hypoglycemic drugs as tolbutamide, new quinolone antibacterial drugs as enoxacin, lithium preparation as lithium carbonate and benzothiadiazine diuretics as hydroflumethiazide and hydrochlorothiazide